Literature DB >> 12498002

GM-CSF treatment for Crohn's disease: a stimulating new therapy?

Jacque N Wilk1, Joanne L Viney.   

Abstract

Crohn's disease (CD) has been classically viewed as an overactive intestinal immune response to the normal constituents of the gut flora. Most therapeutic strategies to date have tried to suppress this overactive adaptive immune response. Recently, a novel, rather alternative therapeutic strategy has been proposed, wherein the approach is to stimulate the innate immune system with growth factors. This review will take a closer look at this unconventional hypothesis and the data that support it, and will place the information in the context of some of the other biological and experimental therapies currently under consideration for the treatment of CD.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12498002

Source DB:  PubMed          Journal:  Curr Opin Investig Drugs        ISSN: 1472-4472


  3 in total

1.  Sargramostim in patients with Crohn's disease: results of a phase 1-2 study.

Authors:  Masakazu Takazoe; Toshiyuki Matsui; Satoshi Motoya; Takayuki Matsumoto; Toshifumi Hibi; Mamoru Watanabe
Journal:  J Gastroenterol       Date:  2009-04-08       Impact factor: 7.527

2.  Heterozygous nucleotide-binding oligomerization domain-2 mutations affect monocyte maturation in Crohn's disease.

Authors:  Marilena Granzotto; Elisa Fabbro; Massimo Maschio; Stefano Martelossi; Sara Quaglia; Alberto Tommasini; Gianni Presani; Alessandro Ventura
Journal:  World J Gastroenterol       Date:  2007-12-14       Impact factor: 5.742

3.  Treatment of Crohn's disease with colony-stimulating factors: An overview.

Authors:  Luisa Guidi; Giammarco Mocci; Manuela Marzo; Sergio Rutella
Journal:  Ther Clin Risk Manag       Date:  2008-10       Impact factor: 2.423

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.